ClinicalTrials.gg
CompletedNCT04882540Updated Mar 13, 2023Results posted

A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects

A Phase 1 interventional study of brivaracetam in Healthy Participants, sponsored by UCB Biopharma SRL. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-13.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
30th of 34
12 · median 94
Started
2021
with 2 others
Phase 1
6 of 34
1 open now
Registered
29th of 34
by date
Lead sponsor
7 of 34
UCB Biopharma SRL

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 30th largest by enrollment, is one of 3 that started in 2021, is one of 6 in phase 1, and was the 29th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

The purpose of the study is to assess the pharmacokinetics, safety, and tolerability of brivaracetam after a single dose and multiple doses in healthy adult Chinese Study Participants.

03

Conditions studied

  • Healthy Participants

Browse trials for

Keywords

  • Epilepsy
  • Healthy participants
  • Phase 1
  • Brivaracetam
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written form is signed and dated by the subject
  • Subject is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule, or medication intake according to the judgment of the Investigator
  • Subjects are Chinese males and females born in China between 18 and 45 years of age (both inclusive) whose parents are of Chinese origin
  • Subjects with (BMI) from 19 to 24 kg/m\^2 (both inclusive). Minimum body weight is equal to or more than 50 kg
  • Subjects with supine blood pressure levels of between 90 to 150 and 60 to 90 mmHg (inclusive) for systolic and diastolic, respectively, with pulse rate of 50 to 100 beats per minute (bpm) (supine position, inclusive) at Screening Visit
  • Subjects without abnormalities in a standard 12-lead (ECG) at Screening Visit judged by the Investigators
  • Subjects with laboratory values within the reference range at Screening Visit, or those with values exceeding the reference range but judged by the Investigators to be not clinically significant to their participation in the study

Exclusion criteria

Exclusion Criteria:

  • Subject has participated in another study of an medicinal product (IMP) (or a medical device) within the previous 30 days or is currently participating in another study of an IMP (or a medical device)
  • Subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study
  • Pregnant, lactating, or sexually active women with who are not using a medically accepted method
  • Subject has a known to any components of the IMP or any of its
  • Subjects with any previous or current cardiovascular, respiratory, hepatic, renal, digestive, endocrine, or nervous system disorder that may affect absorption, secretion, metabolism, or excretion of the investigational product per Investigator judgement
  • Subjects showing a positive result for surface antigen, virus antibody, antibody, or syphilis test at Screening Visit
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    brivaracetam

    This is a Single-Arm study with Single- and Multiple- Dose Periods. Study participants will receive a single dose of brivaracetam (BRV) on Day 1 and will then receive multiple doses of brivaracetam from Day 5-10.

    Drug: brivaracetam

Interventions

  • * Pharmaceutical form: Film-coated tablets * Concentration: 100 mg tablets * Route of administration: Oral use

    Also known as: Briviact

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of BRV and Its Metabolites (Ucb-42145, Ucb-100406-1, ucb107092-1) After Single Dose

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  2. Plasma Concentration of BRV and Its Metabolites (Ucb-42145, Ucb-100406-1, ucb107092-1) After Multiple Dose

    Time frame: Predose on Day 5, 6, 7, 8, and 9; Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  3. Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measured Concentration Above the Limit of Quantification (AUC(0-t)) of Brivaracetam for Single Dose

    AUC(0-t) was defined as the area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification.

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  4. Maximum Observed Plasma Concentration (Cmax) of Brivaracetam for Single Dose

    Cmax was defined as the maximum observed plasma concentration.

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  5. Area Under the Plasma Concentration-time Curve From 0 to 12 Hours at Steady State (AUC(0-12),ss) of Brivaracetam for Multiple Dose

    AUC(0-12),ss was defined as the area under the plasma concentration-time curve from 0 to 12 hours at steady state.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours postdose

  6. Maximum Plasma Concentration at Steady State (Cmax,ss) of Brivaracetam for Multiple Dose

    Cmax,ss was defined as the maximum plasma concentration at steady state.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  7. Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent AEs (TEAEs) were defined as those events that start on or after the time of first investigational medicinal product (IMP) administration, or whose severity worsens on or after the date of first administration of the IMP.

    Time frame: From Baseline to the end of Safety Follow-up (approximately 6 weeks)

Secondary outcomes

  1. Time to Reach Maximum Concentration (Tmax) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose

    Tmax was defined as the time to reach maximum concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  2. Terminal Elimination Half-life (t1/2) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose

    t1/2 was defined as the terminal elimination half-life. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  3. Rate Constant of Elimination (λz) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose

    λz was defined as the rate constant of elimination. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  4. Mean Residence Time (MRT) of Brivaracetam in Plasma for Single Dose

    MRT was defined as the mean residence time.

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  5. Area Under the Plasma Concentration-time Curve From 0 to Infinite Time (AUC) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 for Single Dose

    AUC was defined as the area under the plasma concentration-time curve from 0 to infinite time. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  6. Apparent Total Body Clearance (CL/F) of Brivaracetam in Plasma for Single Dose

    CL/F was defined as the apparent total body clearance.

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  7. Apparent Volume of Distribution (Vz/F) of Brivaracetam in Plasma for Single Dose

    Vz/F was defined as the apparent volume of distribution.

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  8. Cmax of Ucb-42145, Ucb-100406-1 and ucb107092-1 for Single Dose

    Cmax was defined as the maximum plasma concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  9. AUC (0-t) of Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose

    AUC(0-t) was defined as the area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

    Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  10. Tmax of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose

    tmax is the time to reach maximum plasma concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  11. t1/2 of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose

    t1/2 is the terminal elimination half-life. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  12. λz of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose

    λz is the rate constant of elimination. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  13. Minimum Plasma Concentration at Steady State (Cmin,ss) of Brivaracetam in Plasma for Multiple Dose

    Cmin,ss is the minimum plasma concentration at steady state.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  14. Average Plasma Concentration at Steady State (Cav,ss) of Brivaracetam in Plasma for Multiple Dose

    Cav,ss is the average plasma concentration at steady state.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  15. Apparent Total Body Clearance at Steady State (CLss/F) of Brivaracetam in Plasma for Multiple Dose

    CLss/F is the apparent total body clearance at steady state.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  16. Vz/F of Brivaracetam in Plasma for Multiple Dose

    Vz/F is the apparent volume of distribution.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  17. Cmax,ss of Ucb-42145, Ucb-100406-1, and ucb107092-1 in Plasma for Multiple Dose

    Cmax,ss is the maximum plasma concentration at steady state. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  18. Area Under the Curve From 0 to 12 Hours at Steady State (AUC(0-12),ss) of Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose

    AUC(0-12),ss is the area under the curve from 0 to 12 hours at steady state. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours postdose

  19. Peak Trough Fluctuation (PTF) of Brivaracetam in Steady-state for Multiple Dose

    PTF was calculated as (Cmax,ss-Cmin,ss)/Cav,ss.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

  20. Accumulation Ratio Calculated From AUC at Steady State and AUC After Single Dose (RAUC) of Brivaracetam for Multiple Dose

    Accumulation ratio (RAUC) was calculated as AUC(0-12),ss divided by AUC(0-12).

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours postdose

  21. Accumulation Ratio Calculated From Cmax at Steady State and Cmax After Single Dose (Rmax) of Brivaracetam for Multiple Dose

    Accumulation ratio (Rmax) was calculated as Cmax,ss divided by Cmax.

    Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose

07

Results

Posted Mar 13, 2023

Participant flow

The study started to enroll study participants in May 2021 and concluded in June 2021.

Participant flow — Overall Study
MilestoneBrivaracetam
Started12
Completed12
Not completed0

Outcome measures

PrimaryPlasma Concentration of BRV and Its Metabolites (Ucb-42145, Ucb-100406-1, ucb107092-1) After Single Dose
Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Plasma Concentration of BRV and Its Metabolites (Ucb-42145, Ucb-100406-1, ucb107092-1) After Single Dose
nanograms/milliliter (ng/mL)Brivaracetam
BRV- Day 1: PredoseNA ± NA
BRV- Day 1: 0.25 hour postdose1039 ± 134
BRV- Day 1: 0.50 hour postdose2610 ± 46.2
BRV- Day 1: 1 hour postdose2725 ± 19.6
BRV- Day 1: 1.5 hours postdose2458 ± 15.9
BRV- Day 1: 2 hours postdose2602 ± 18.2
BRV- Day 1: 3 hours postdose2387 ± 21.3
BRV- Day 1: 4 hours postdose2181 ± 22.8
BRV- Day 1: 6 hours postdose1793 ± 22.4
BRV- Day 1: 9 hours postdose1389 ± 27.8
BRV- Day 1: 12 hours postdose1064 ± 28.8
BRV- Day 1: 16 hours postdose747.7 ± 32.7
BRV- Day 1: 24 hours postdose423.8 ± 45.9
BRV- Day 1: 36 hours postdose157.6 ± 64.4
BRV- Day 1: 48 hours postdose68.75 ± 86.6
BRV- Day 1: 72 hours postdose9.372 ± 229
ucb-42145- Day 1: PredoseNA ± NA
ucb-42145- Day 1: 0.25 hour postdose4.480 ± 131
ucb-42145- Day 1: 0.50 hour postdose27.48 ± 66.8
ucb-42145- Day 1: 1 hour postdose78.18 ± 31.8
ucb-42145- Day 1: 1.5 hours postdose130.5 ± 19.6
ucb-42145- Day 1: 2 hours postdose155.9 ± 22.8
ucb-42145- Day 1: 3 hours postdose187.8 ± 30.3
ucb-42145- Day 1: 4 hours postdose149.4 ± 21.8
ucb-42145- Day 1: 6 hours postdose122.5 ± 16.5
ucb-42145- Day 1: 9 hours postdose112.6 ± 25.0
ucb-42145- Day 1: 12 hours postdose75.73 ± 26.3
ucb-42145- Day 1: 16 hours postdose59.17 ± 26.6
ucb-42145- Day 1: 24 hours postdose37.46 ± 38.4
ucb-42145- Day 1: 36 hours postdose12.82 ± 50.8
ucb-42145- Day 1: 48 hours postdose6.222 ± 64.1
ucb-42145- Day 1: 72 hours postdoseNA ± NA
ucb-100406-1- Day 1: PredoseNA ± NA
ucb-100406-1- Day 1: 0.25 hour postdose7.364 ± 146
ucb-100406-1- Day 1: 0.5 hour postdose29.78 ± 88.5
ucb-100406-1- Day 1: 1 hour postdose39.97 ± 81.2
ucb-100406-1- Day 1: 1.5 hour postdose44.11 ± 78.5
ucb-100406-1- Day 1: 2 hours postdose52.59 ± 84.7
ucb-100406-1- Day 1: 3 hours postdose63.15 ± 83.9
ucb-100406-1- Day 1: 4 hours postdose73.57 ± 85.1
ucb-100406-1- Day 1: 6 hours postdose87.58 ± 85.6
ucb-100406-1- Day 1: 9 hours postdose91.89 ± 88.2
ucb-100406-1- Day 1: 12 hours postdose86.76 ± 88.6
ucb-100406-1- Day 1: 16 hours postdose78.88 ± 87.0
ucb-100406-1- Day 1: 24 hours postdose52.44 ± 86.2
ucb-100406-1- Day 1: 36 hours postdose22.54 ± 77.8
ucb-100406-1- Day 1: 48 hours postdose10.35 ± 72.1
ucb-100406-1- Day 1: 72 hours postdoseNA ± NA
ucb107092-1- Day 1: PredoseNA ± NA
ucb107092-1- Day 1: 0.25 hour postdoseNA ± NA
ucb107092-1- Day 1: 0.5 hour postdoseNA ± NA
ucb107092-1- Day 1: 1 hour postdose4.404 ± 62.9
ucb107092-1- Day 1: 1.5 hours postdose9.800 ± 32.1
ucb107092-1- Day 1: 2 hours postdose16.17 ± 22.6
ucb107092-1- Day 1: 3 hours postdose27.06 ± 18.3
ucb107092-1- Day 1: 4 hours postdose37.89 ± 22.1
ucb107092-1- Day 1: 6 hours postdose41.59 ± 16.3
ucb107092-1- Day 1: 9 hours postdose38.77 ± 25.1
ucb107092-1- Day 1: 12 hours postdose28.37 ± 20.8
ucb107092-1- Day 1: 16 hours postdose21.85 ± 22.0
ucb107092-1- Day 1: 24 hours postdose14.49 ± 28.7
ucb107092-1- Day 1: 36 hours postdose6.443 ± 23.4
ucb107092-1- Day 1: 48 hours postdose3.976 ± 29.0
ucb107092-1- Day 1: 72 hours postdoseNA ± NA
PrimaryPlasma Concentration of BRV and Its Metabolites (Ucb-42145, Ucb-100406-1, ucb107092-1) After Multiple Dose
Time frame:
Predose on Day 5, 6, 7, 8, and 9; Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of BRV and Its Metabolites (Ucb-42145, Ucb-100406-1, ucb107092-1) After Multiple Dose
ng/mLBrivaracetam
BRV- Day 5: PredoseNA ± NA
BRV- Day 6: Predose1743 ± 33.6
BRV- Day 7: Predose1981 ± 36.3
BRV- Day 8: Predose1955 ± 38.4
BRV- Day 9: Predose1975 ± 41.7
BRV- Day 10: Predose1918 ± 34.2
BRV- Day 10: 0.25 hour postdose2888 ± 54.0
BRV- Day 10: 0.5 hour postdose4582 ± 45.6
BRV- Day 10: 1 hour postdose4448 ± 30.2
BRV- Day 10: 1.5 hour postdose4583 ± 21.5
BRV- Day 10: 2 hours postdose4421 ± 22.1
BRV- Day 10: 3 hours postdose4037 ± 23.3
BRV- Day 10: 4 hours postdose3671 ± 26.2
BRV- Day 10: 6 hours postdose2956 ± 26.7
BRV- Day 10: 9 hours postdose2241 ± 32.4
BRV- Day 10: 12 hours postdose1702 ± 38.4
BRV- Day 10: 16 hours postdose1185 ± 44.1
BRV- Day 10: 24 hours postdose614.7 ± 57.6
BRV- Day 10: 36 hours postdose216.1 ± 75.3
BRV- Day 10: 48 hours postdose93.68 ± 95.8
BRV- Day 10: 72 hours postdose17.75 ± 154
ucb-42145- Day 5: PredoseNA ± NA
ucb-42145- Day 6: Predose153.6 ± 25.7
ucb-42145- Day 7: Predose185.8 ± 26.0
ucb-42145- Day 8: Predose181.1 ± 28.1
ucb-42145- Day 9: Predose193.1 ± 34.1
ucb-42145- Day 10: Predose166.6 ± 34.9
ucb-42145- Day 10: 0.25 hour postdose156.1 ± 38.3
ucb-42145- Day 10: 0.5 hour postdose177.0 ± 35.6
ucb-42145- Day 10: 1 hour postdose247.8 ± 34.5
ucb-42145- Day 10: 1.5 hour postdose265.2 ± 28.5
ucb-42145- Day 10: 2 hours postdose293.2 ± 26.2
ucb-42145- Day 10: 3 hours postdose357.2 ± 21.1
ucb-42145- Day 10: 4 hours postdose291.6 ± 27.0
ucb-42145- Day 10: 6 hours postdose199.9 ± 24.2
ucb-42145- Day 10: 9 hours postdose185.1 ± 28.4
ucb-42145- Day 10: 12 hours postdose123.7 ± 32.3
ucb-42145- Day 10: 16 hours postdose111.4 ± 33.7
ucb-42145- Day 10: 24 hours postdose54.35 ± 42.9
ucb-42145- Day 10: 36 hours postdose17.39 ± 59.5
ucb-42145- Day 10: 48 hours postdose9.114 ± 67.4
ucb-42145- Day 10: 72 hours postdoseNA ± NA
ucb-100406-1- Day 5: PredoseNA ± NA
ucb-100406-1- Day 6: Predose146.9 ± 78.9
ucb-100406-1- Day 7: Predose188.1 ± 75.4
ucb-100406-1- Day 8: Predose209.2 ± 72.1
ucb-100406-1- Day 9: Predose217.0 ± 71.3
ucb-100406-1- Day 10: Predose218.2 ± 71.8
ucb-100406-1- Day 10: 0.25 hour postdose221.2 ± 70.8
ucb-100406-1- Day 10: 0.5 hour postdose238.2 ± 67.6
ucb-100406-1- Day 10: 1 hour postdose243.9 ± 67.5
ucb-100406-1- Day 10: 1.5 hours postdose258.2 ± 70.9
ucb-100406-1- Day 10: 2 hours postdose249.9 ± 67.8
ucb-100406-1- Day 10: 3 hours postdose248.3 ± 69.1
ucb-100406-1- Day 10: 4 hours postdose254.3 ± 70.9
ucb-100406-1- Day 10: 6 hours postdose238.7 ± 68.7
ucb-100406-1- Day 10: 9 hours postdose229.0 ± 70.1
ucb-100406-1- Day 10: 12 hours postdose212.2 ± 76.0
ucb-100406-1- Day 10: 16 hours postdose171.7 ± 73.1
ucb-100406-1- Day 10: 24 hours postdose111.6 ± 72.8
ucb-100406-1- Day 10: 36 hours postdose41.71 ± 72.8
ucb-100406-1- Day 10: 48 hours postdose19.41 ± 66.7
ucb-100406-1- Day 10: 72 hours postdose2.771 ± 75.0
ucb107092-1- Day 5: PredoseNA ± NA
ucb107092-1- Day 6: Predose51.71 ± 22.0
ucb107092-1- Day 7: Predose63.87 ± 27.2
ucb107092-1- Day 8: Predose65.14 ± 25.5
ucb107092-1- Day 9: Predose71.64 ± 23.3
ucb107092-1- Day 10: Predose68.47 ± 23.8
ucb107092-1- Day 10: 0.25 hour postdose62.74 ± 21.9
ucb107092-1- Day 10: 0.5 hour postdose63.76 ± 19.6
ucb107092-1- Day 10: 1 hour postdose65.20 ± 20.0
ucb107092-1- Day 10: 1.5 hours postdose68.84 ± 22.1
ucb107092-1- Day 10: 2 hours postdose71.72 ± 18.9
ucb107092-1- Day 10: 3 hours postdose82.18 ± 20.2
ucb107092-1- Day 10: 4 hours postdose84.04 ± 15.2
ucb107092-1- Day 10: 6 hours postdose80.87 ± 20.2
ucb107092-1- Day 10: 9 hours postdose69.25 ± 23.6
ucb107092-1- Day 10: 12 hours postdose52.96 ± 17.8
ucb107092-1- Day 10: 16 hours postdose42.69 ± 21.1
ucb107092-1- Day 10: 24 hours postdose28.57 ± 25.4
ucb107092-1- Day 10: 36 hours postdose13.15 ± 26.1
ucb107092-1- Day 10: 48 hours postdose8.580 ± 32.0
ucb107092-1- Day 10: 72 hours postdose3.380 ± 52.9
PrimaryArea Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measured Concentration Above the Limit of Quantification (AUC(0-t)) of Brivaracetam for Single Dose

AUC(0-t) was defined as the area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification.

Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · hours*nanograms per milliliter (h*ng/mL)
Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measured Concentration Above the Limit of Quantification (AUC(0-t)) of Brivaracetam for Single Dose
hours*nanograms per milliliter (h*ng/mL)Brivaracetam
Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measured Concentration Above the Limit of Quantification (AUC(0-t)) of Brivaracetam for Single Dose35730 ± 28.7
PrimaryMaximum Observed Plasma Concentration (Cmax) of Brivaracetam for Single Dose

Cmax was defined as the maximum observed plasma concentration.

Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Brivaracetam for Single Dose
ng/mLBrivaracetam
Maximum Observed Plasma Concentration (Cmax) of Brivaracetam for Single Dose3334 ± 22.2
PrimaryArea Under the Plasma Concentration-time Curve From 0 to 12 Hours at Steady State (AUC(0-12),ss) of Brivaracetam for Multiple Dose

AUC(0-12),ss was defined as the area under the plasma concentration-time curve from 0 to 12 hours at steady state.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours postdose
Reported as:
Geometric least squares mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From 0 to 12 Hours at Steady State (AUC(0-12),ss) of Brivaracetam for Multiple Dose
h*ng/mLBrivaracetam
Area Under the Plasma Concentration-time Curve From 0 to 12 Hours at Steady State (AUC(0-12),ss) of Brivaracetam for Multiple Dose36760 ± 27.8
PrimaryMaximum Plasma Concentration at Steady State (Cmax,ss) of Brivaracetam for Multiple Dose

Cmax,ss was defined as the maximum plasma concentration at steady state.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration at Steady State (Cmax,ss) of Brivaracetam for Multiple Dose
ng/mLBrivaracetam
Maximum Plasma Concentration at Steady State (Cmax,ss) of Brivaracetam for Multiple Dose5215 ± 27.7
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent AEs (TEAEs) were defined as those events that start on or after the time of first investigational medicinal product (IMP) administration, or whose severity worsens on or after the date of first administration of the IMP.

Time frame:
From Baseline to the end of Safety Follow-up (approximately 6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
ParticipantsBrivaracetam
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study12
SecondaryTime to Reach Maximum Concentration (Tmax) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose

Tmax was defined as the time to reach maximum concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Median · hour
Time to Reach Maximum Concentration (Tmax) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose
hourBrivaracetam
Brivaracetam1.000 (0.500 to 3.00)
ucb-421453.000 (1.50 to 6.00)
ucb-100406-19.000 (6.00 to 12.0)
ucb107092-16.000 (4.00 to 9.00)
SecondaryTerminal Elimination Half-life (t1/2) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose

t1/2 was defined as the terminal elimination half-life. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Mean · hour
Terminal Elimination Half-life (t1/2) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose
hourBrivaracetam
Brivaracetam9.628 ± 2.229
ucb-4214510.40 ± 2.716
ucb-100406-110.24 ± 1.696
ucb107092-112.38 ± 1.019
SecondaryRate Constant of Elimination (λz) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose

λz was defined as the rate constant of elimination. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · 1/hour
Rate Constant of Elimination (λz) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose
1/hourBrivaracetam
Brivaracetam0.07370 ± 22.7
ucb-421450.06866 ± 25.3
ucb-100406-10.06847 ± 15.9
ucb107092-10.05614 ± 8.10
SecondaryMean Residence Time (MRT) of Brivaracetam in Plasma for Single Dose

MRT was defined as the mean residence time.

Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · hour
Mean Residence Time (MRT) of Brivaracetam in Plasma for Single Dose
hourBrivaracetam
Mean Residence Time (MRT) of Brivaracetam in Plasma for Single Dose13.02 ± 18.8
SecondaryArea Under the Plasma Concentration-time Curve From 0 to Infinite Time (AUC) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 for Single Dose

AUC was defined as the area under the plasma concentration-time curve from 0 to infinite time. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From 0 to Infinite Time (AUC) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 for Single Dose
h*ng/mLBrivaracetam
Brivaracetam36000 ± 29.1
ucb-421452567 ± 25.4
ucb-100406-12530 ± 81.5
ucb107092-1878.2 ± 21.1
SecondaryApparent Total Body Clearance (CL/F) of Brivaracetam in Plasma for Single Dose

CL/F was defined as the apparent total body clearance.

Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · Liter per hour (L/h)
Apparent Total Body Clearance (CL/F) of Brivaracetam in Plasma for Single Dose
Liter per hour (L/h)Brivaracetam
Apparent Total Body Clearance (CL/F) of Brivaracetam in Plasma for Single Dose2.777 ± 29.1
SecondaryApparent Volume of Distribution (Vz/F) of Brivaracetam in Plasma for Single Dose

Vz/F was defined as the apparent volume of distribution.

Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/F) of Brivaracetam in Plasma for Single Dose
LiterBrivaracetam
Apparent Volume of Distribution (Vz/F) of Brivaracetam in Plasma for Single Dose37.69 ± 10.8
SecondaryCmax of Ucb-42145, Ucb-100406-1 and ucb107092-1 for Single Dose

Cmax was defined as the maximum plasma concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Cmax of Ucb-42145, Ucb-100406-1 and ucb107092-1 for Single Dose
ng/mLBrivaracetam
ucb-42145193.3 ± 27.7
ucb-100406-193.16 ± 88.0
ucb107092-143.18 ± 21.1
SecondaryAUC (0-t) of Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose

AUC(0-t) was defined as the area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

Time frame:
Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · h*ng/mL
AUC (0-t) of Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose
h*ng/mLBrivaracetam
ucb-421452503 ± 25.4
ucb-100406-12423 ± 85.2
ucb107092-1799.2 ± 21.1
SecondaryTmax of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose

tmax is the time to reach maximum plasma concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Median · hour
Tmax of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose
hourBrivaracetam
Brivaracetam0.5000 (0.250 to 2.00)
ucb-421453.000 (2.00 to 4.00)
ucb-100406-11.500 (1.00 to 6.00)
ucb107092-14.000 (0.00 to 6.02)
Secondaryt1/2 of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose

t1/2 is the terminal elimination half-life. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Mean · hour
t1/2 of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose
hourBrivaracetam
Brivaracetam10.25 ± 1.749
ucb-4214510.15 ± 2.198
ucb-100406-19.645 ± 1.067
ucb107092-114.85 ± 2.334
Secondaryλz of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose

λz is the rate constant of elimination. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · 1/hour
λz of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose
1/hourBrivaracetam
Brivaracetam0.06860 ± 17.9
ucb-421450.06984 ± 22.4
ucb-100406-10.07228 ± 11.3
ucb107092-10.04721 ± 16.5
SecondaryMinimum Plasma Concentration at Steady State (Cmin,ss) of Brivaracetam in Plasma for Multiple Dose

Cmin,ss is the minimum plasma concentration at steady state.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Minimum Plasma Concentration at Steady State (Cmin,ss) of Brivaracetam in Plasma for Multiple Dose
ng/mLBrivaracetam
Minimum Plasma Concentration at Steady State (Cmin,ss) of Brivaracetam in Plasma for Multiple Dose1696 ± 38.2
SecondaryAverage Plasma Concentration at Steady State (Cav,ss) of Brivaracetam in Plasma for Multiple Dose

Cav,ss is the average plasma concentration at steady state.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Average Plasma Concentration at Steady State (Cav,ss) of Brivaracetam in Plasma for Multiple Dose
ng/mLBrivaracetam
Average Plasma Concentration at Steady State (Cav,ss) of Brivaracetam in Plasma for Multiple Dose3064 ± 27.8
SecondaryApparent Total Body Clearance at Steady State (CLss/F) of Brivaracetam in Plasma for Multiple Dose

CLss/F is the apparent total body clearance at steady state.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · L/h
Apparent Total Body Clearance at Steady State (CLss/F) of Brivaracetam in Plasma for Multiple Dose
L/hBrivaracetam
Apparent Total Body Clearance at Steady State (CLss/F) of Brivaracetam in Plasma for Multiple Dose2.720 ± 27.8
SecondaryVz/F of Brivaracetam in Plasma for Multiple Dose

Vz/F is the apparent volume of distribution.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · Liter
Vz/F of Brivaracetam in Plasma for Multiple Dose
LiterBrivaracetam
Vz/F of Brivaracetam in Plasma for Multiple Dose39.65 ± 14.8
SecondaryCmax,ss of Ucb-42145, Ucb-100406-1, and ucb107092-1 in Plasma for Multiple Dose

Cmax,ss is the maximum plasma concentration at steady state. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Cmax,ss of Ucb-42145, Ucb-100406-1, and ucb107092-1 in Plasma for Multiple Dose
ng/mLBrivaracetam
ucb-42145357.9 ± 21.6
ucb-100406-1264.8 ± 68.8
ucb107092-188.53 ± 16.1
SecondaryArea Under the Curve From 0 to 12 Hours at Steady State (AUC(0-12),ss) of Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose

AUC(0-12),ss is the area under the curve from 0 to 12 hours at steady state. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Curve From 0 to 12 Hours at Steady State (AUC(0-12),ss) of Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose
h*ng/mLBrivaracetam
ucb-421452644 ± 23.5
ucb-100406-12844 ± 70.0
ucb107092-1867.1 ± 18.3
SecondaryPeak Trough Fluctuation (PTF) of Brivaracetam in Steady-state for Multiple Dose

PTF was calculated as (Cmax,ss-Cmin,ss)/Cav,ss.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · ratio
Peak Trough Fluctuation (PTF) of Brivaracetam in Steady-state for Multiple Dose
ratioBrivaracetam
Peak Trough Fluctuation (PTF) of Brivaracetam in Steady-state for Multiple Dose1.131 ± 24.2
SecondaryAccumulation Ratio Calculated From AUC at Steady State and AUC After Single Dose (RAUC) of Brivaracetam for Multiple Dose

Accumulation ratio (RAUC) was calculated as AUC(0-12),ss divided by AUC(0-12).

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours postdose
Reported as:
Geometric mean · ratio
Accumulation Ratio Calculated From AUC at Steady State and AUC After Single Dose (RAUC) of Brivaracetam for Multiple Dose
ratioBrivaracetam
Accumulation Ratio Calculated From AUC at Steady State and AUC After Single Dose (RAUC) of Brivaracetam for Multiple Dose1.677 ± 12.6
SecondaryAccumulation Ratio Calculated From Cmax at Steady State and Cmax After Single Dose (Rmax) of Brivaracetam for Multiple Dose

Accumulation ratio (Rmax) was calculated as Cmax,ss divided by Cmax.

Time frame:
Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · ratio
Accumulation Ratio Calculated From Cmax at Steady State and Cmax After Single Dose (Rmax) of Brivaracetam for Multiple Dose
ratioBrivaracetam
Accumulation Ratio Calculated From Cmax at Steady State and Cmax After Single Dose (Rmax) of Brivaracetam for Multiple Dose1.564 ± 30.4

Adverse events

Collected over From Day 1 to the end of Safety Follow-up (approximately 6 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brivaracetam0/12 (0%)0/12 (0%)12/12 (100%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventBrivaracetam
DizzinessNervous system disorders10/12
SomnolenceNervous system disorders7/12
DiarrhoeaGastrointestinal disorders4/12
AstheniaGeneral disorders3/12
Electrocardiogram QT prolongedInvestigations3/12
AtaxiaNervous system disorders3/12
NeutrophiliaBlood and lymphatic system disorders1/12
Atrioventricular block first degreeCardiac disorders1/12
Ventricular extrasystolesCardiac disorders1/12
PalpitationsCardiac disorders1/12

Baseline characteristics

The Safety Set consisted of all participants who received at least 1 dose of BRV.

Age, Categorical
Age, Categorical(Participants)Brivaracetam
<=18 years0
Between 18 and 65 years12
>=65 years0
Age, Continuous
Age, Continuous(years)Brivaracetam
Mean29.9 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Brivaracetam
Female6
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brivaracetam
Asian12
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brivaracetam
Not Hispanic or Latino12
08

Study locations

1 site
  • Ep0101 101
    Shanghai, Shanghai, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jun 2021, 0 months.

Results were first posted in Mar 2023, 1 year 9 months after primary completion.

Of 34 industry-sponsored phase 1 interventional studies under Epilepsy, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 0 months is below that.

Counting every sponsor, half of 55 studies reached it within 8 months; a quarter within 3 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2021
First posted
May 12, 2021
StartActual
May 19, 2021
Primary completionActual
Jun 8, 2021
CompletionActual
Jun 8, 2021
Results first posted
Mar 13, 2023
Last update
Mar 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04882540
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
May 12, 2021
Start date
May 19, 2021
Primary completion
Jun 8, 2021
Completion
Jun 8, 2021
Results posted
Mar 13, 2023
Last update
Mar 13, 2023

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion